Chemomab Therapeutics Ltd. (CMMB) stock
CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.62+0.09 (+5.88%)
Close on Nov 16, 2026Market cap $11.65MP/E 1.1Yield –
Chemomab Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Chemomab Therapeutics's total assets was $10.24M at Jun 30, 2026. For fiscal 2025 it was $13.81M, down 18.6% from the year before. The highest annual figure on record is $64.35M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.81M | -18.6% |
| FY2024 | Dec 31, 2024 | $16.96M | -23.4% |
| FY2023 | Dec 31, 2023 | $22.15M | -48.6% |
| FY2022 | Dec 31, 2022 | $43.06M | -33.1% |
| FY2021 | Dec 31, 2021 | $64.35M | +415.8% |
| FY2020 | Dec 31, 2020 | $12.48M | -36.8% |
| FY2019 | Dec 31, 2019 | $19.76M | +54.8% |
| FY2018 | Dec 31, 2018 | $12.76M | +511.5% |
| FY2017 | Dec 31, 2017 | $2.09M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.24M | -29.6% |
| Q4 FY2025 | Dec 31, 2025 | $13.81M | -37.6% |
| Q2 FY2025 | Jun 30, 2025 | $11.13M | -61.4% |
| Q4 FY2024 | Dec 31, 2024 | $16.96M | -51.5% |
| Q2 FY2024 | Jun 30, 2024 | $14.54M | -66.2% |
| Q4 FY2023 | Dec 31, 2023 | $22.15M | -55.9% |
| Q2 FY2023 | Jun 30, 2023 | $28.85M | -48.8% |
| Q1 FY2023 | Mar 31, 2023 | $35.01M | -42.6% |
| Q4 FY2022 | Dec 31, 2022 | $43.06M | -33.1% |
| Q3 FY2022 | Sep 30, 2022 | $50.22M | -25.5% |
| Q2 FY2022 | Jun 30, 2022 | $56.38M | -20.1% |
| Q1 FY2022 | Mar 31, 2022 | $60.96M | +1.4% |
| Q4 FY2021 | Dec 31, 2021 | $64.35M | +415.8% |
| Q3 FY2021 | Sep 30, 2021 | $67.44M | +777.1% |
| Q2 FY2021 | Jun 30, 2021 | $70.52M | +604.1% |
| Q1 FY2021 | Mar 31, 2021 | $60.12M | +296.0% |
| Q4 FY2020 | Dec 31, 2020 | $12.48M | -36.8% |
| Q3 FY2020 | Sep 30, 2020 | $7.69M | -39.7% |
| Q2 FY2020 | Jun 30, 2020 | $10.02M | +379.9% |
| Q1 FY2020 | Mar 31, 2020 | $15.18M | – |
| Q4 FY2019 | Dec 31, 2019 | $19.76M | – |
| Q4 FY2018 | Dec 31, 2018 | $12.76M | – |
| Q4 FY2017 | Dec 31, 2017 | $2.09M | – |
See a number that looks wrong?